Stool CMV, in Visit Clinic

CMV in the bowel is infection of the intestinal lining by cytomegalovirus that causes colitis or enteritis, most often in immunocompromised people. Symptoms include abdominal pain, diarrhea (sometimes bloody), fever and weight loss. Diagnosis uses endoscopy with biopsy, PCR or antigen testing. Severe cases cause ulcers, bleeding or perforation. Treatment is antiviral therapy, typically ganciclovir or valganciclovir, plus supportive care.

CMV is usually diagnosed by blood PCR, serology, or tissue biopsy. Stool testing for CMV DNA is not a routine or reliable diagnostic method—its sensitivity and clinical value are variable—so a negative stool result doesn’t rule out disease. For suspected CMV colitis, clinicians rely on endoscopic biopsy with histology/PCR and blood viral load testing to confirm infection and guide treatment.

A positive CMV test can mean different things: IgG indicates past exposure and likely immunity; IgM or PCR indicates recent or active infection. In healthy adults it’s often mild, but it can harm unborn babies and immunocompromised people. If positive, get confirmatory tests and discuss management with your clinician—pregnant women and immunosuppressed patients need prompt evaluation and monitoring.

Cytomegalovirus (CMV) usually causes mild or no symptoms in healthy people, so it is not generally serious for most adults. However, it can be serious in newborns (congenital CMV), causing hearing loss and developmental problems, and in people with weakened immune systems (e.g., transplant recipients, advanced HIV), where it can cause severe organ damage. Pregnant women and immunocompromised individuals should seek medical guidance.

Many people with cytomegalovirus (CMV) are asymptomatic. When symptoms appear early they often resemble mononucleosis: low-grade fever, fatigue, sore throat, swollen lymph nodes, muscle aches and headache. In newborns early signs include jaundice, low birth weight, petechial rash, enlarged liver/spleen, poor feeding and seizures. Immunocompromised people may develop fever, weight loss, diarrhea, pneumonia or vision changes.

CMV cannot be completely cured because it establishes lifelong latency. In healthy people it often needs no treatment. Active or severe CMV—especially in newborns or immunocompromised patients—is treated with antivirals (ganciclovir, valganciclovir, foscarnet) to control infection and prevent complications. Antiviral prophylaxis is used in high‑risk settings; vaccines and improved therapies are under research.